These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 14601754)

  • 1. Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.
    Gilbert PB; Bosch RJ; Hudgens MG
    Biometrics; 2003 Sep; 59(3):531-41. PubMed ID: 14601754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials.
    Shepherd BE; Gilbert PB; Jemiai Y; Rotnitzky A
    Biometrics; 2006 Jun; 62(2):332-42. PubMed ID: 16918897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial.
    Mehrotra DV; Li X; Gilbert PB
    Biometrics; 2006 Sep; 62(3):893-900. PubMed ID: 16984333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mark-specific hazard ratio model with multivariate continuous marks: an application to vaccine efficacy.
    Juraska M; Gilbert PB
    Biometrics; 2013 Jun; 69(2):328-37. PubMed ID: 23421613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation.
    Gilbert PB; Sun Y
    Biostatistics; 2005 Jul; 6(3):374-94. PubMed ID: 15831584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the analysis of viral load endpoints in HIV vaccine trials.
    Hudgens MG; Hoering A; Self SG
    Stat Med; 2003 Jul; 22(14):2281-98. PubMed ID: 12854093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmented designs to assess immune response in vaccine trials.
    Follmann D
    Biometrics; 2006 Dec; 62(4):1161-9. PubMed ID: 17156291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types.
    Gilbert PB; Self SG; Ashby MA
    Biometrics; 1998 Sep; 54(3):799-814. PubMed ID: 9750238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On modeling the effects of T-cell vaccines on HIV acquisition and disease.
    Wick WD
    Stat Med; 2008 Oct; 27(23):4805-16. PubMed ID: 18265425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials.
    Wick WD; Gilbert PB; Self SG
    PLoS Comput Biol; 2006 Jun; 2(6):e64. PubMed ID: 16789816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chop-lump tests for vaccine trials.
    Follmann D; Fay MP; Proschan M
    Biometrics; 2009 Sep; 65(3):885-93. PubMed ID: 19210727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop.
    Follmann D; Duerr A; Tabet S; Gilbert P; Moodie Z; Fast P; Cardinali M; Self S
    J Acquir Immune Defic Syndr; 2007 Jan; 44(1):49-60. PubMed ID: 17075387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporating founder virus information in vaccine field trials.
    Follmann D; Huang CY
    Biometrics; 2015 Jun; 71(2):386-96. PubMed ID: 25773491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity analyses comparing time-to-event outcomes only existing in a subset selected postrandomization and relaxing monotonicity.
    Shepherd BE; Gilbert PB; Dupont CT
    Biometrics; 2011 Sep; 67(3):1100-10. PubMed ID: 21114663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semiparametric methods for multiple exposure mismeasurement and a bivariate outcome in HIV vaccine trials.
    Golm GT; Halloran ME; Longini IM
    Biometrics; 1999 Mar; 55(1):94-101. PubMed ID: 11318183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of placebos in Phase 1 preventive HIV vaccine clinical trials.
    Huang Y; Karuna ST; Janes H; Frahm N; Nason M; Edlefsen PT; Kublin JG; Corey L; McElrath MJ; Gilbert PB
    Vaccine; 2015 Feb; 33(6):749-52. PubMed ID: 25454855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.
    Huang Y; Follmann D; Nason M; Zhang L; Huang Y; Mehrotra DV; Moodie Z; Metch B; Janes H; Keefer MC; Churchyard G; Robb ML; Fast PE; Duerr A; McElrath MJ; Corey L; Mascola JR; Graham BS; Sobieszczyk ME; Kublin JG; Robertson M; Hammer SM; Gray GE; Buchbinder SP; Gilbert PB
    PLoS One; 2015; 10(9):e0136626. PubMed ID: 26332672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating candidate principal surrogate endpoints.
    Gilbert PB; Hudgens MG
    Biometrics; 2008 Dec; 64(4):1146-54. PubMed ID: 18363776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interpretability and robustness of sieve analysis models for assessing HIV strain variations in vaccine efficacy.
    Gilbert PB
    Stat Med; 2001 Jan; 20(2):263-79. PubMed ID: 11169601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Causal inference for vaccine effects on infectiousness.
    Halloran ME; Hudgens MG
    Int J Biostat; 2012 Jan; 8(2):. PubMed ID: 22499732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.